The promise of big data

Every patient experience generates a massive amount of data which, when pooled together, can give a detailed account of their health, the effectiveness & safety of the drugs they are taking and when aggregated from other patient’s data a vast library of information about entire disease states and clinical populations.

Understandably pharma is now armouring itself with vast amount of IT infrastructure and providing patient interface technologies to collect this ‘big data’ and be able to develop more effective, personalised medicines with a greater value proposition to healthcare payers. For healthcare payers this data is enabling the shift of focus from reaction to prevention, which hopefully will cuts costs considerably and lead to better patient outcomes. Through consolidating data from millions of patients, both pharma & healthcare providers hope to see distinctive patterns in patient’s disease & clinical responses to a given treatment; and this has inevitably lead to many interesting partnerships.

This ebook collects together some of the most exciting projects in Real World Big Data collection today.

Download ebook now

Highlights include:

1. Pfizer and Humedica strategic alliance to advance capabilities to derive insights from real world data
2. Kaiser Permanente and the largest EHR system in the world
3. Aetna launches the Aetna Innovation Labs to look at Big Data
4. The AstraZeneca and WellPoint collaboration – How pharma is relooking at its challenges
5. The sleeping dragon – Novartis’ investment in big data

Download ebook now

Interested in hearing from some of these companies, as they discuss their case studies and success stories?  Join us at Evidence USA 2013 this October in Boston.  For more information about the event, click here to visit our website

If you are interested in speaking or sponsoring this event please contact Nick Longworth on +44 (0) 207 608 7064 or nlongworth@healthnetworkcommunications.com

We spoke to approximately 200 representatives from this field, and they were all optimistic about stem cells, and were especially excited about the increase in successful clinical data that they see on the horizon. We were inspired by these conversations with industry, and decided to share them with you in the format of this report – the top 15 most promising cell therapies.

Download the report here.

The ranking is based on research conducted with leading biotechs, developing stem cells, cell and gene therapies, as well as with government, universities and research institutions.

The selection criteria included:

• Recent successful clinical data
• Effective capital formation strategies
• Stock history
• Awareness across different markets
• Personal recognition

Want to know who made the cut? Get a copy of the report now!

If you are interested in this, you may also be interested in Stem Cells & Regenerative Medicine Congress, taking place in Cambridge, MA on September 30 – October 1.

Click here to watch the video

We asked some industry experts from top pharma companies how they believe global austerity measures are impacting pharma?

This video includes insights from representatives from:

• Alliance Life Sciences
• Vision Health Care Consultancy
• Patients Direct

If you would like to download the e-book that accompanies this video then >click here

This video was produced in the run up to the Evidence USA conference and exhibition, if you would like more information about this event then >click here to visit the website

If you want to tweet us follow us @totalbiopharma or follow the debate on #evidenceus

Download the report here.

A few years ago there were just a few companies that could be considered promising in the cell and gene therapy space with a next-to-launch status. But, today more and more companies have been emerging with promising approaches and cell and gene therapies under development.

The ranking in the report was based on research conducted with leading and emerging companies working in the stem cells, cell and gene therapies space, as well as regulators, patient groups and academic institutions.

The selection criteria included:

• Recent increased clinical attrition
• The ability to deploy capital formation strategies
• Published studies
• Awareness across different markets
• Personal recognition

Download the report now to find out who made the list!

Did we miss anyone? Let me know – I value your feedback.

For more information on cell and gene therapy, check out Stem Cells & Regenerative Medicine Congress, taking place in Cambridge, MA this September.

Geoff MacKay,

Download his presentation slides for insights on:

• Organogenesis platform cellular technology
• Overview of development timeline
• FDA review team structure
• Regulatory review milestones
• Transition to commercialization

Download the slides now!

For more information on the 2013 event, download the prospectus here or visit our website.

>Click here to download ebook

We have compiled a list of the Top 100 twitter profiles in evidence development. The final 100 have been chosen based on their activity, engagement, followers and overall quality of twitter contributions. Additionally we have compiled the list to reflect the many stakeholders in these discussions – patients, physicians, pharma, payers, publications.

This Ebook was developed during the production of the Evidence USA conference & exhibition, taking place in Boston, 23-24th October this year. For more information about this event >Click here to visit the website.

We hope that you enjoy the list and find it informative! But if you have any comments or questions or think that we have missed someone important tweet them to us @totalbiopharma #evidenceusa

>Click here to download the ebook

The 6^th annual BioPharma Asia Convention 2013 took place on the 18 – 21 March at Resorts World Sentosa, Singapore. Over 2000 senior level attendees joined us in Singapore last month to meet, network, and discuss latest industry trends, partnership models and investment opportunities in Asia’s emerging biopharma industry.

Download post event report

Download sample delegate list

Across the four days of strategic content driven programme and intensive networking sessions, this event saw a total of:

• Over 800 senior level (directors and above) industry professionals
• Over 180 speakers
• More than 2,000 face-to-face meetings were pre-arranged and scheduled onsite
• More than 200 presentation sessions
• 76% of attendees from Asia
• 45% of attendees are President/Chairman/CEO level
• 36% of attendees from both global and Asian pharma and biotechs
• Over 50 networking hours
• Over 39 countries represented

Download the post event report here

Missed out on all the networking opportunities and good fun? No frets!

Book your calendar now for the 7^th annual BioPharma Asia Convention 2013, 10 – 13 March, Marina Bay Sands, Singapore

Download the event prospectus here

Visit our website here

Early bird sponsorship and exhibition opportunities available
Contact Rebecca Koh now at +65 6322 2725 or rebecca.koh@terrapinn.com to share with us your business objectives in Asia and let us help you customize an effective participation experience to meet these business needs.

Enquire about speaking opportunities here

Don’t just take our word for it….

“Our experience has been very good. In fact, this is the first time I’m attending the BioPharma Asia conference but I find it very interesting. The morning plenary session was really very interesting and thought provoking. I am participating as a Chairman for the Sustainable Manufacturing programme and it was really interesting to learn more about Singapore’s energy management organization and that gave me a lot of new ideas. I think this is a very good opportunity for me.”

Sanjit Singh Lamba, President and Managing Director, Eisai, India

“I like it! I think there is more interest in Asia, more development is going on in Asia and Asia is getting wealthier. It is nice to see the positive changes in Asia as well.”

Nikolai Tankovich, CEO, Stemedica, USA

“Participation in this conference has really been in line with our objectives of growth in Asia, it allows us to really reach out to a number of our clients. It also allowed us to move forward in a more significant way in terms of making sure that we have a good understanding of where the industry is and what the industry needs.”

Lim Bee Koong, Director, Healthcare Strategy, UPS Asia Pacific, Singapore

“This is much larger than our original expectations because we know Singapore is a small country even though I know it is a very active country. But I did not expect so many people came from the different countries. So this is also much exciting and larger conference than expected.”

Yoshiya Oda, Unit President, Biomarkers & Personalized Medicine, Eisai, USA

“It’s good. The mix of audience that we have here, the delegates and exhibitors have been very good for us. We have been in contact with some of them who have potential business interest in our products so that obviously is a good thing for us as an exhibitor. The logistics and arrangements are also been very well taken care so there is no hassle that we have to go through.”

Prashant Bhavaraju, Chief Marketing Officer, Acceliant, USA

“I’ve had a really good experience hearing from really good speakers. There were good and diversified topics with different speakers coming from different regions not only Asia, but also US and Europe”

Maria D’Orazio, Head of Cold Chain Logistics, Novartis Vaccines & Diagnostics, Italy

“It’s been great so far, it’s a tremendous meeting. I think that the multiple tracks have made it quite interesting, lots of different colleagues across multiple industries, whether its manufacturing or clinical trials or marketing. It’s a really nice way to see all of these colleagues at once. I think that the informational sessions have been great as well.”

Kent Thoelke, Executive Vice President, Scientific and Medical Affairs, PRA, USA
We look forward to seeing you in 2014!

With 10 hotly contested awards open for nomination, make your votes count for individuals and organisations that have shown best in class in 2012/2013.

Make your nominations here and we look forward to announcing the Winners at the star studded ROAR Awards Ceremony and Gala Dinner at the 4th World Orphan Drug Congress Europe, in Geneva on the 14th November 2013.

>Click here to download the ebook

We have compiled a list of the Top 25 influencers in evidence development. The final 25 have been chosen based on their experience, career achievements and contributions to evidence development.

This list has been compiled during the production of our Evidence USA conference, taking place in Boston on 22-23 October this year. For more information about this event >Click here to visit the website.

We hope that you enjoy the list and find it informative! But if you have any comments or questions or think that we have missed someone important tweet them to us @totalbiopharma #evidenceusa

>Click here to download the ebook

Sheri Nidositko,

Download the presentation slides here.

The slides address topics like:

• IBP’s assignments and the relationship to the cell line development process and its challenges
• Integrated biologics profiling
• Cell line development workflow
• Evaluation of different vector technologies (internal and external):
  • FACS-vector (NVS)
  • Folate receptor selection system (interim results, NVS + Technion)
  • Targeted integration (interim results, NVS + Cellectis S.A.)
• Impact of new technologies on platform performance

If you want to know more about any of these topics, download the slides now.

For more information on cell line development, check out Cell Culture World Congress USA 2013. You can download the prospectus here.